4640 Results

People

  1. Saltz
    Saltz
  2. O'Reilly
    O'Reilly
  3. Abou-Alfa
    Abou-Alfa
  4. Kelsen
    Kelsen
  5. Ilson
    Ilson
  6. Kemeny
    Kemeny
  7. Janjigian
    Janjigian
  8. Reidy
    Reidy
  9. Jarnagin
    Jarnagin
  10. D'Angelica
    D'Angelica

Groups

  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)
  7. Epidemiology and Biostatistics (828)
  8. GSK Faculty (793)
  9. Department of Pathology and Laboratory Medicine (723)
  10. Biostatistics Service (661)
  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Provider insights on managing patients on immunotherapy, barriers to clinical trials, and biomarker testing preferences
    Meeting Abstract

    Ackbarali, T.; Neal, J.; Janjigian, Y.; Overman, M.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in "cold" and I-O refractory metastatic solid tumors
    Meeting Abstract

    Wilky, B.; El-Khoueiry, A.; Bullock, A.; Tsimberidou, A.; Mahadevan, D.; Margolin, K.; Trent, J.; Bockorny, B.; Moser, J.; Hosein, P.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors: Initial dose-escalation results
    Meeting Abstract

    Johnson, M.; Lakhani, N.; Girda, E.; Olszanski, A.; Fong, L.; Han, H.; Casey, K.; Li, S.; Visich, J.; Skokos, D.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Exploratory platform trial to evaluate immunotherapy combinations with chemotherapy for the treatment of patients with previously untreated metastatic pancreatic adenocarcinoma (REVOLUTION)
    Meeting Abstract

    Lyman, J.; O'Reilly, E.; Wainberg, Z.; Fisher, G.; Wolff, R.; Ko, A.; O'Hara, M.; Singh, H.; Amaravadi, R.; Kimmelman, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
    Meeting Abstract

    Sanborn, R.; Gabrail, N.; Carneiro, B.; O'Hara, M.; Bordoni, R.; Gordon, M.; Khalil, D.; Hauke, R.; Taglienti, C.; Rogalski, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Immunogenicity of durvalumab: Analysis of pooled pan-tumor data
    Meeting Abstract

    El-Khoueiry, A.; Zhou, D.; Ozguroglu, M.; Johnson, M.; Abou-Alfa, G.; Makowsky, M.; Krug, L.; Gupta, A.; Chen, C.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial
    Meeting Abstract

    Saatcioglu, H. D.; Valle, J.; Macarulla, T.; Javle, M.; Oh, D. Y.; Goyal, L.; Conway, J.; Iyer, J.; Najdawi, F.; Shah, C.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition
    Meeting Abstract

    Bortone, D.; Monette, A.; Tschernia, N.; Cogdill, A.; Najjar, Y.; Sweis, R. F.; Valpione, S.; Wennerberg, E.; Bommareddy, P.; Haymaker, C.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • PD-1 blockade in solid tumors with defects in polymerase epsilon
    Meeting Abstract

    Rousseau, B.; Bieche, I.; Pasmant, E.; Hamzaoui, N.; Leulliot, N.; Michon, L.; de Reynies, A.; Foote, M.; Masliah-Planchon, J.; Svrcek, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
    Meeting Abstract

    Lei, M.; Janjigian, Y. Y.; Ajani, J. A.; Moehler, M.; Wang, X.; Shen, L.; Garrido, M.; Gallardo, C.; Yamaguchi, K.; Wyrwicz, L.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save